ArticleMedicine2026
U-shaped association between estimated glomerular filtration rate and mortality in HSV-positive adults: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Although estimated glomerular filtration rate (eGFR) is a key indicator of kidney function, its association with mortality in herpes simplex virus (HSV)-seropositive individuals remains unclear. We analyzed 17,848 HSV-1/HSV-2 seropositive participants from National Health and Nutrition Examination Survey (1999-2016). The eGFR was calculated using standard equations, and mortality data were linked to the National Death Index through December 31, 2019. Kaplan-Meier survival curves, Cox regression models, generalized additive models, and stratified analyses were used to assess the association between eGFR and all-cause and cardiovascular mortality. The mean age of participants was 33.85 years (standard deviation: 9.4), and the average eGFR was 110.4 mL/min/1.73 m2 (standard deviation: 18.7). During a median follow-up of 141 months, 598 participants (3.35%) died from all causes, and 139 (0.78%) died from cardiovascular causes. A U-shaped association was observed between eGFR and all-cause mortality. Below an inflection point of 85.22 mL/min/1.73 m2, each 10-unit increase in eGFR was associated with reduced risk of all-cause death (hazard ratio = 0.70; 95% confidence interval: 0.64-0.75; P < .0001). Above this threshold, higher eGFR was associated with increased mortality (hazard ratio = 1.12; 95% confidence interval: 1.05-1.20; P = .001). Similar trends were found for cardiovascular mortality, although the association with elevated eGFR was not statistically significant. These findings were consistent across stratified and sensitivity analyses. In HSV-infected individuals, eGFR showed a nonlinear relationship with mortality. Moderate eGFR levels were associated with the lowest mortality risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.